Cartesian Therapeutics 重症肌无力III期Aurora试验关键数据预计2027年一季度公布 生物制品许可申请计划于2027年中提交

美股速递
May 26

Cartesian Therapeutics公司宣布,针对重症肌无力的III期Aurora临床试验的关键顶线数据预计将于2027年第一季度获得。公司计划在此之后,于2027年中期向监管机构提交生物制品许可申请。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10